NICE technology appraisal guidance
Issued: August 2009
TA176
Cetuximab for the first-line treatment of metastatic colorectal cancer
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta176
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp